CRISPR Therapeutics and the broader biomedical and genetics industry were operating within the medical sector, with stock performance noted against the S&P 500 on July 16, 2025.
1 report, 1 independent
Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CRISPR Therapeutics and the broader biomedical and genetics industry were operating within the medical sector, with stock performance noted against the S&P 500 on July 16, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
CRISPR Therapeutics
company in Basel, Switzerland
Nothing else this week.
Related events
- CRISPR Therapeutics is discussing commercial priorities and expanding treatment access into new markets with an investment bank.
- CRISPR Therapeutics and Scribe Therapeutics presented at a Morgan Stanley conference, highlighting their competition in gene-editing therapeutics.
- CRISPR Therapeutics presented durability data on gene therapy at the European Society of Cardiology (ESC) Congress on August 28, 2026.
Coverage
Newest first; wire copies grouped- ZacksCRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors CRISPR Therapeutics AG (CRSP) ended the recent trading session at $52.73, demonstrating a -6.54% change from th